Considering the latest advances on immunotherapy of TNBC, it is worth mentioning that an FDA-approved combination of anti-programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitor (atezolizumab) plus nab-paclitaxel immunotherapy carries the potential of a more promising management of locally advanced or metastatic TNBC through tumor-specific and durable responses, but for a limited number of patients [52]. Here, CD274 is linked to neoplasm.